377 results on '"Kharfan-Dabaja M"'
Search Results
2. The Role of Radiation Therapy in the Management of Gray Zone Lymphoma
3. Consolidative Radiotherapy for Residual PET-Avid Disease on Day +30 Post CAR T-Cell Therapy in Non-Hodgkin Lymphoma
4. SINGLE CELL ANALYSIS REVEALS IMMUNE DYSFUNCTION IN LARGE B CELL LYMPHOMA (LBCL) PTS WITH HYPOMAGNESEMIA RECEIVING AXI‐CEL: RESULTS FROM ZUMA‐1 TRIAL AND MAYO CLINIC COHORT
5. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis
6. Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?
7. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention
8. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma
9. Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT
10. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes
11. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation
12. Inhibition of FLT3 in AML: a focus on sorafenib
13. The Impact of Radiation Timing in Peri-CAR T-Cell Therapy on Local Control for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
14. Comprehensive Salvage Radiotherapy for Limited Relapsed B-Cell Non-Hodgkin Lymphoma Following CD19 Chimeric Antigen Receptor T-Cell Therapy
15. Bridging Radiotherapy for Patients with Limited (
16. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma
17. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation
18. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
19. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma
20. Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature
21. High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review
22. G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis
23. Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis
24. New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?
25. Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT
26. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!
27. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors
28. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission
29. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience
30. Radiation Therapy as Bridging Treatment to CAR T Cell Therapy in Non-Hodgkin Lymphoma
31. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
32. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure
33. Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers
34. IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
35. PROGRESSION‐FREE SURVIVAL AT 24 MONTHS AS A LANDMARK AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
36. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T‐CELL LYMPHOMA: COMPARABLE OUTCOMES OF HAPLO‐IDENTICAL VS. MATCHED DONORS. A CIBMTR & EBMT ANALYSIS
37. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis
38. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review
39. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes
40. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity
41. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease
42. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease
43. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD
44. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation
45. ALLOGENEIC TRANSPLANTATION (HCT) FOR AGGRESSIVE MATURE T/NK CELL MALIGNANCIES: A SINGLE INSTITUTION EXPERIENCE: PH-AB025
46. EARLY OCCURRENCE OF SEVERE HYPOALBUMINEMIA IS ASSOCIATED WITH ACUTE GVHD ONSET AND GRADING AFTER ALLOGENEIC HCT: PH-P410
47. High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation
48. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature
49. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
50. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.